Sintetica’s eye gel approved in USA

Sintetica has received approval from the Food and Drug Administration (FDA) for its eye anesthetic Iheezo. This gel product is used during surgical procedures to numb the surface of the eye. According to a press release, Iheezo is the first approved application of the active substance chloroprocaine hydrochloride in the North American ophthalmology market and the first branded eye anesthetic to be approved there for almost 14 years. To achieve this, the Ticino-based pharmaceutical company’s approval group worked together with Harrow Health, which specializes in ophthalmology and is based in Nashville, Tennessee.

According to the information provided, the most recent study showed that Iheezo not only provides sufficient anesthesia for a surgical procedure within at most one and a half minutes, but also no individuals treated with Iheezo required additional therapy to complete a surgical procedure. Sintetica’s CEO, Nicola Caronzolo, commented: “I am particularly proud of this important milestone, which exemplifies the quality of Sintetica’s research and development groups and our ability to innovate – to be a global pharmaceuticals leader.”

CEO of Harrow Mark L. Baum stated: “We have always believed in the unique clinical value of IHEEZO.” He added: “It has the potential to become an indispensable premium tool for eyecare professionals and their patients requiring ocular surface anesthesia.”